ストックスクリーナーアプリを入手
0.58
9.39%
0.0498
アフターアワーズ：
.57
-0.01
-1.72%
前日終値:
$0.5302
開ける：
$0.525
24時間の取引高:
1.04M
Relative Volume:
0.71
時価総額：
$56.77M
収益：
-
当期純損益:
$-30.54M
株価収益率:
-0.3742
EPS:
-1.55
ネットキャッシュフロー:
$-18.30M
1週間 パフォーマンス:
-7.48%
1か月 パフォーマンス:
-28.49%
6か月 パフォーマンス:
+38.13%
1年 パフォーマンス:
-37.63%
1日の値動き範囲:
$0.521
$0.58
1週間の範囲:
$0.51
$0.6302
52週間の値動き範囲:
$0.202
$1.818
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
名前
Unicycive Therapeutics Inc
セクター
電話
650-384-0642
住所
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
UNCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
0.58 | 56.77M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-04 | 開始されました | Piper Sandler | Overweight |
Unicycive Therapeutics Inc (UNCY) 最新ニュース
Unicycive highlights challenges in phosphate management - MSN
Unicycive Therapeutics' (UNCY) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Unicycive Therapeutics Announces the Publication of Patient - GlobeNewswire
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science - GlobeNewswire Inc.
Here's Why We're Watching Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Situation - Yahoo Finance
Analyzing Imunon (NASDAQ:IMNN) & Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Update - MarketBeat
Unicycive Therapeutics’ (UNCY) Buy Rating Reiterated at HC Wainwright - Defense World
Unicycive Therapeutics Receives Notice of Non-Compliance from Nasdaq - Defense World
Unicycive Therapeutics (NASDAQ:UNCY) Receives "Buy" Rating from HC Wainwright - MarketBeat
Unicycive Therapeutics granted extension to meet Nasdaq compliance - Investing.com
Unicycive Therapeutics granted extension to meet Nasdaq compliance By Investing.com - Investing.com Canada
Unicycive reports positive phase 1 results for kidney drug By Investing.com - Investing.com Australia
Unicycive reports positive phase 1 results for kidney drug - Investing.com
Unicycive Therapeutics Announces Publication of Positive - GlobeNewswire
Unicycive's OLC Drug Shows Strong Safety Profile in Phase 1 Trial, FDA Decision Due 2025 - StockTitan
Unicycive Therapeutics Inc (NASDAQ: UNCY) Is A Safe Investment Now, Isn’t It? - Stocks Register
Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics - The Manila Times
Unicycive Therapeutics Announces Publication of - GlobeNewswire
Unicycive Therapeutics (NASDAQ:UNCY) and Arvinas (NASDAQ:ARVN) Head-To-Head Review - Defense World
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Decline in Short Interest - MarketBeat
Unicycive Therapeutics Inc (NASDAQ: UNCY): Overvalued In Comparison To Others? - Stocks Register
Analyzing Unicycive Therapeutics (NASDAQ:UNCY) and FibroGen (NASDAQ:FGEN) - Defense World
We're Hopeful That Unicycive Therapeutics (NASDAQ:UNCY) Will Use Its Cash Wisely - Simply Wall St
5,000,000 Shares in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Purchased by Walleye Capital LLC - MarketBeat
Acuta Capital Partners LLC Takes $807,000 Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - MarketBeat
Breakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - Yahoo Finance
Great Point Partners LLC Takes $3.49 Million Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - MarketBeat
Unicycive's SWOT analysis: CKD treatment innovator's stock faces pivotal year - Investing.com India
Unicycive Therapeutics (UNCY) Price Target Increased by 14.13% to 4.46 - MSN
Unicycive Therapeutics (NASDAQ:UNCY) Receives "Speculative Buy" Rating from Benchmark - MarketBeat
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Unicycive Therapeutics to Participate in Two Upcoming - GlobeNewswire
Unicycive Therapeutics CEO to Present at Noble Capital and Piper Sandler Healthcare Conferences | UNCY Stock News - StockTitan
Logos Global Management LP Adjusts Stake in Unicycive Therapeuti - GuruFocus.com
RA Capital Management's Strategic Acquisition of Unicycive Thera - GuruFocus.com
Great Point Partners LLC's Strategic Investment in Unicycive The - GuruFocus.com
Walleye Capital LLC Acquires New Stake in Unicycive Therapeutics Inc - GuruFocus.com
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Unicycive's OLC Drug Gets FDA Review Date, Reports Strong Q3 Pipeline Progress | UNCY Stock News - StockTitan
USFDA accepts Shilpa Medicare CDMO partner Unicycive NDA for Oxylanthanum Carbonate - Medical Dialogues
Unicycive Therapeutics (NASDAQ:UNCY) Given Buy Rating at HC Wainwright - MarketBeat
Unicycive shares hold as FDA accepts NDA for kidney treatment By Investing.com - Investing.com UK
Shilpa Medicare update on its CDMO partnerUnicycive Therapeutics - Business Standard
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - Marketscreener.com
Unicycive eyes June FDA verdict for hyperphosphataemia drug - pharmaphorum
Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia - MarketWatch
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - The Manila Times
Unicycive Therapeutics Inc (UNCY) 財務データ
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):